CR20170529A - Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2. - Google Patents

Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2.

Info

Publication number
CR20170529A
CR20170529A CR20170529A CR20170529A CR20170529A CR 20170529 A CR20170529 A CR 20170529A CR 20170529 A CR20170529 A CR 20170529A CR 20170529 A CR20170529 A CR 20170529A CR 20170529 A CR20170529 A CR 20170529A
Authority
CR
Costa Rica
Prior art keywords
inhibitor
bcl
combined therapy
antibody anti
mdm2
Prior art date
Application number
CR20170529A
Other languages
English (en)
Inventor
Markus Dangl
Christian Klein
Frank Herting
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20170529A publication Critical patent/CR20170529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere a la terapia combinada de un anticuerpo anti-CD20 con un inhibidor de Bcl-2 y un inhibidor de MDM2 para el tratamiento del cáncer, especialmente a la terapia combinada de cánceres que expresan CD20 con un anticuerpo anti-CD20 de tipo I o un anticuerpo B-Ly1 humanizado no fucosilado y un inhibidor de Bcl-2 y un inhibidor de MDM2.
CR20170529A 2015-05-26 2016-05-23 Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2. CR20170529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15169199 2015-05-26
PCT/EP2016/061517 WO2016188935A1 (en) 2015-05-26 2016-05-23 Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor

Publications (1)

Publication Number Publication Date
CR20170529A true CR20170529A (es) 2018-01-26

Family

ID=53264535

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170529A CR20170529A (es) 2015-05-26 2016-05-23 Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2.

Country Status (31)

Country Link
US (1) US20160347852A1 (es)
EP (1) EP3302549B1 (es)
JP (1) JP6612362B2 (es)
KR (1) KR102043803B1 (es)
CN (1) CN107847600B (es)
AR (1) AR104735A1 (es)
AU (1) AU2016267564B2 (es)
BR (1) BR112017023517A2 (es)
CA (1) CA2984706A1 (es)
CL (1) CL2017002983A1 (es)
CR (1) CR20170529A (es)
DK (1) DK3302549T3 (es)
ES (1) ES2744624T3 (es)
HK (1) HK1252855A1 (es)
HR (1) HRP20191585T1 (es)
HU (1) HUE044853T2 (es)
IL (1) IL255353B (es)
LT (1) LT3302549T (es)
MA (1) MA44645B1 (es)
MX (1) MX2017014977A (es)
MY (1) MY188849A (es)
NZ (1) NZ736727A (es)
PE (1) PE20180454A1 (es)
PL (1) PL3302549T3 (es)
PT (1) PT3302549T (es)
RS (1) RS59204B1 (es)
RU (1) RU2727196C2 (es)
SI (1) SI3302549T1 (es)
UA (1) UA124617C2 (es)
WO (1) WO2016188935A1 (es)
ZA (1) ZA201707357B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200110711A (ko) 2012-09-07 2020-09-24 제넨테크, 인크. Ｉｉ형 항-ｃｄ20 항체와 선택적 ｂｃｌ-2 억제제와의 병용 치료요법
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019101789A1 (en) * 2017-11-22 2019-05-31 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
EP3737681A4 (en) 2018-01-10 2022-01-12 Recurium IP Holdings, LLC BENZAMIDE COMPOUNDS
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US11491167B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
JP2021516262A (ja) * 2018-07-31 2021-07-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド リツキシマブ及び／若しくはベンダムスチンと組み合わされたＢｃｌ−２阻害剤又はＣＨＯＰと組み合わされたＢｃｌ−２阻害剤の相乗的な抗腫瘍効果
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
BR112013014522A2 (pt) * 2010-12-16 2017-09-26 Roche Glycart Ag anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer

Also Published As

Publication number Publication date
PL3302549T3 (pl) 2019-11-29
US20160347852A1 (en) 2016-12-01
JP2018515583A (ja) 2018-06-14
MX2017014977A (es) 2018-03-23
IL255353A0 (en) 2017-12-31
CL2017002983A1 (es) 2018-05-04
UA124617C2 (uk) 2021-10-20
EP3302549A1 (en) 2018-04-11
AR104735A1 (es) 2017-08-09
RU2017145649A (ru) 2019-06-26
ES2744624T3 (es) 2020-02-25
CN107847600A (zh) 2018-03-27
IL255353B (en) 2021-08-31
ZA201707357B (en) 2020-05-27
DK3302549T3 (da) 2019-09-16
MY188849A (en) 2022-01-09
CN107847600B (zh) 2021-09-03
KR20180004285A (ko) 2018-01-10
MA44645B1 (fr) 2019-09-30
BR112017023517A2 (pt) 2018-07-24
HK1252855A1 (zh) 2019-06-06
PE20180454A1 (es) 2018-03-05
RU2727196C2 (ru) 2020-07-21
HRP20191585T1 (hr) 2019-11-29
KR102043803B1 (ko) 2019-11-12
HUE044853T2 (hu) 2019-11-28
AU2016267564B2 (en) 2022-09-01
NZ736727A (en) 2022-09-30
SI3302549T1 (sl) 2019-10-30
PT3302549T (pt) 2019-09-09
CA2984706A1 (en) 2016-12-01
AU2016267564A1 (en) 2017-11-16
RU2017145649A3 (es) 2019-10-23
EP3302549B1 (en) 2019-07-03
WO2016188935A1 (en) 2016-12-01
JP6612362B2 (ja) 2019-11-27
LT3302549T (lt) 2019-09-25
RS59204B1 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
CR20170529A (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2.
NZ718792A (en) Combination therapy of an anti cd20 antibody with a btk inhibitor
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
GEP20217331B (en) Anti-tigit antibodies
ECSP17008984A (es) Tratamientos conjuntos con anticuerpos anti cd40
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
FI3500299T3 (fi) Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
PE20180315A1 (es) Anticuerpos para cd40
BR112017026027A2 (pt) combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
IL280421A (en) Cancer treatment by antibody
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.
GB201813138D0 (en) Cancer treatment with an antibody